Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation

Liver Transplantation

Volumn 17, Issue 12, 2011, Pages 1474-1480

  Venturi, Carla ^a   Bueno, Javier ^b   Castells, Lluís ^b   Quintero, Jesus ^b   Casas, Isabel ^b   Allende, Helena ^b   Martinez Ibañez, Vicente ^b   Charco, Ramõn ^a,b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADOLESCENT; ARTICLE; CHILD; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; MALE; PEDIATRIC SURGERY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; VIRAL CLEARANCE;

ADOLESCENT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; RNA, VIRAL; SPAIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 82455219359     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22439     Document Type: Article

References (40)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562. (Pubitemid 29384163)
2. Wirth S, Kelly D, Sokal E, Socha P, Mieli-Vergani G, Dhawan A, et al. Guidance for clinical trials for children and adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2011; 52: 233-237.
3. Vogt M, Lang T, Frösner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-870. (Pubitemid 29427048)
4. Posthouwer D, Fischer K, van Erpecum KJ, Mauser-Bunschoten EP,. The natural history of childhood-acquired hepatitis C infection in patients with inherited bleeding disorders. Transfusion 2006; 46: 1360-1366. (Pubitemid 44117964)
5. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-507.
6. Sokal EM, Bourgois A, Stéphenne X, Silveira T, Porta G, Gardovska D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827-831.
7. Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, et al.; for Peds-C Clinical Research Network. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-458.
8. Bortolotti F, Verucchi G, Cammà C, Cabibbo G, Zancan L, Indolfi G, et al.; for Italian Observatory for HCV Infection and Hepatitis C in Children. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134: 1900-1907. (Pubitemid 351783258)
9. Barshes NR, Udell IW, Lee TC, O'Mahony CA, Karpen SJ, Carter BA, Goss JA,. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transpl 2006; 12: 1119-1123. (Pubitemid 44063787)
10. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317-322.
11. Vargas V, Comas P, Castells L, Quer J, Esteban JI, Allende E, et al. Incidence and outcome of hepatitis C virus infection after liver transplantation. Transpl Int 1994; 7 (suppl 1): S216-S220.
12. Féray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 1137-1143. (Pubitemid 24323557)
13. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896. (Pubitemid 34267271)
14. Gane EJ,. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (suppl 2): S36-S44.
15. Prieto M, Berenguer M, Rayõn JM, Cõrdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-256. (Pubitemid 29024010)
16. Martell M, Esteban JI, Quer J, Genescà J, Weiner A, Esteban R, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-3229.
17. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973. (Pubitemid 41401136)
18. Margarit C, Martínez Ibañez V, Tormo R, Infante D, Iglesias H,. Maintenance immunosuppression without steroids in pediatric liver transplantation. Transplant Proc 1989; 21 (pt 2): 2230-2231. (Pubitemid 19131199)
19. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435. (Pubitemid 12218164)
20. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293. (Pubitemid 26260021)
21. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663.
22. McDiarmid SV, Conrad A, Ament ME, Vargas J, Martin MG, Goss JA, Busuttil RW,. De novo hepatitis C in children after liver transplantation. Transplantation 1998; 66: 311-318. (Pubitemid 28390211)
23. Pastore M, Willems M, Cornu C, Buts JP, Reding R, de Ville de Goyet J, et al. Role of hepatitis C virus in chronic liver disease occurring after orthotopic liver transplantation. Arch Dis Child 1995; 72: 403-407.
24. Forns X, Martínez-Bauer E, Feliu A, García-Retortillo M, Martín M, Gay E, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology 2005; 41: 115-122. (Pubitemid 40066389)
25. Pol S, Vallet-Pichard A, Fontaine H, Lebray P,. HCV infection and hemodialysis. Semin Nephrol 2002; 22: 331-339. (Pubitemid 34790829)
26. Berenguer M, Prieto M, Rayõn JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (pt 1): 852-858.
27. McCaughan GW, Zekry A,. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002; 8 (suppl 1): S7-S13. (Pubitemid 35154037)
28. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384-393.
29. Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553-561.
30. Dussaix E, de Paillette L, Laurent-Puig P, Martres P, Lykavieris P, Bernard O, Alvarez F,. Hepatitis C virus infection in pediatric liver transplantation. Transplantation 1993; 55: 795-798. (Pubitemid 23122050)
31. Cesaro S, Bortolotti F, Petris MG, Brugiolo A, Guido M, Carli M,. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer 2010; 55: 108-112.
32. González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, et al.; for International Pediatric Hepatitis C Therapy Group. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005; 42: 1010-1018. (Pubitemid 43112667)
33. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
34. Poynard T, Yuen MF, Ratziu V, Lai CL,. Viral hepatitis C. Lancet 2003; 362: 2095-2100. (Pubitemid 38035201)
35. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-1018. (Pubitemid 40593909)
36. Jacobson KR, Murray K, Zellos A, Schwarz KB,. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34: 52-58. (Pubitemid 34251703)
37. Haber B,. Hepatitis C, liver transplantation, and why we should consider children separately. Liver Transpl 2006; 12: 1042-1043. (Pubitemid 44063776)
38. Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805-1812. (Pubitemid 44911807)
39. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067-1076. (Pubitemid 44063780)
40. Fernández I, Ulloa E, Colina F, Abradelo M, Jiménez C, Gimeno A, et al. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C. Liver Transpl 2009; 15: 948-955.